Newsletter Signup | Join Community
First degree relatives of individuals with Melanoma are at increased risk of developing skin cancers.
Keytruda treatment for melanoma improves survival, treats CNS disease and may be most effective when used in combination
Ocular melanoma is an uncommon cancer of the eye requiring aggressive treatment by specialized physicians.
FDA grants "Breakthrough Therapy Designation" for Bempegaldesleukin + Opdivo for previously untreated advanced Melanoma
Genomic testing should be performed in all patients-precision medicines reduce recurrences and prolong survival.
Keytruda immunotherapy + BRAF- MEK Inhibitors combo further delays melanoma progression compared BRAF-MEK alone.
BRAF-MEK combination improves survival in stage III and advanced melanoma with V600E and V600K mutations
Anyone have experience with TVEC? Looking to learn from others. Thanks
A new very active treatment option for Melaoma-Braftovihttps://mavendoctors…